Skip to content

The Efficacy and Safety of Prophylactic Central Lymph Node Dissection in Papillary Thyroid Carcinoma

The Efficacy and Safety of Prophylactic Central Lymph Node Dissection in Papillary Thyroid Carcinoma

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02418390
Enrollment
101
Registered
2015-04-16
Start date
2015-04-01
Completion date
2020-10-08
Last updated
2022-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid Cancer, Papillary

Brief summary

The aim of this study is to investigate the efficacy and safety of prophylactic central lymph node dissection in papillary thyroid carcinoma.

Detailed description

The aim of this study is to investigate the efficacy and safety of prophylactic central lymph node dissection in papillary thyroid carcinoma. Primary outcome is the surgical completeness, recurrence rate, and successful ablation rate. Secondary outcomes are the incidence of postoperative complications and PTC stage. The enrolled patients were randomly assigned to control group and intervention group (1:1 allocation).

Interventions

dissection of level VI compartment by AAHNS (American association of head and neck surgeons) classification

Sponsors

Seoul National University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
20 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

were as follows: 1. patients aged 20 to 70 years old 2. patients diagnosed with PTC or suspicious for PTC on fine needle aspiration or core needle biopsy 3. patients with no evidence of LNM before and during surgery(cN0) 4. patients with no evidence of distant metastasis(cM0).

Exclusion criteria

were as follows: 1. patients suspected of advanced PTC(clinically T3 or T4) such as invasion of peripheral organs on preoperative examination 2. patients who have previous history of cervical radiation therapy or surgery. 3. pregnant women 4. uncontrolled diabetes, hypertension, or chronic renal failure 5. aspirin or anticoagulant medication within 7 days 6. other clinical trial participation within 30 days 7. radiation exposure to the head and neck 8. previous operation to the neck 9. advanced thyroid cancer including adjacent organ invasion

Design outcomes

Primary

MeasureTime frameDescription
The number of participants with successful surgical completenessParticipants will be followed from the operation to 5 year (maximum)In the case of patients undergoing RAI ablation, surgical completeness was defined as cases with a negative ultrasonographic finding with postoperative 1st stimulated Tg \<1 ng/mL. In patients who did not undergo RAI treatment, the case with a negative finding at the 1st postoperative ultrasound with postoperative 1st unstimulated Tg \<0.2ng/mL was defined as surgical completeness.
Recurrence rate of thyroid cancerParticipants will be followed from the operation to 5 year (maximum)Recurrence was defined according to the definition of response to therapy in the 2015 American Thyroid Association(ATA) guidelines.
Number of participants with successful ablationParticipants will be followed from the operation to 5 year (maximum)Successful ablation was defined as a patient whose stimulated Tg level was measured as \<1 ng/mL at last ablation.

Secondary

MeasureTime frameDescription
postoperative complication occurrence rateParticipants will be followed from the operation to 5 year (maximum)At outpatient clinic (6months posteoperatively), video laryngoscopic exam and serum parathyroid hormone with serum calcium will be measured. Type and number of complications will be recorded
impact of prophylactic central lymph node dissection on staging of papillary thyroid cancer(PTC)TNM stage of each case was confirmed after final pathologic reports. At our facility, final pathologic reports would be turned out at an average of 2 weeks after surgeryPostoperative complications was divided into transient complication (\< 6 months) and permanent complication (≥ 6 months) according to the duration. Hypoparathyroidism was diagnosed when patients were given oral calcium supplements to relieve symptoms of hypocalcemia or when serum parathyroid hormone (PTH) levels were lower than baseline values;1) PTH \<10 pg/mL on days 1 and 14 after surgery; and 2) PTH \<15 pg/mL at least 3 months after surgery. All patients underwent a laryngeal ultrasound or laryngoscope after surgery to check for RLN injury. RLN injury was diagnosed when the vocal cord movement was hypomobile or fixed on evaluation. In addition, present study evaluated symptoms related to voice changes, such as hoarseness, thickened voice, difficulty in making high pitch sound, easy voice fatigue, aspiration, or dyspnea in an outpatient clinic.

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026